# Cell-specific Activation of the Nrf2 Antioxidant Pathway Increases Mucosal Inflammation in Acute but Not in Chronic Colitis

- **DOI:** [10.1093/ecco-jcc/jjw172](https://doi.org/10.1093/ecco-jcc/jjw172)
- **Rating:** Sound (3.5 out of 5)
- **Verdict:** Cell-specific constitutive Nrf2 activation convincingly aggravates acute murine colitis, but the underpowered chronic model limits conclusions about disease-stage dependence.
- **Framework version:** v5.8
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-08-19
- **Evaluation page:** https://www.nabu.science/paper/10.1093%2Fecco-jcc%2Fjjw172

## Key claims

1. Expression of caNrf2 either in epithelial cells or myeloid cells resulted in aggravation of DSS-induced acute colitis.
   - Support: Well-supported
   - Type: Primary finding
   - Basis: two cell-specific models showed concordant worsening across complementary acute-colitis outcomes
   - Location: Abstract; Results, Figures 1–2
2. Aggravation of inflammation by caNrf2 was not observed in the IL-10-/- model of spontaneous chronic colitis, where even a trend towards reduced prolapse rate was observed.
   - Support: Tentative
   - Type: Secondary
   - Basis: the chronic design relies on underpowered null comparisons and non-significant sex-stratified trends
   - Location: Abstract; Results, Figures 5–6
3. Our findings show that a well balanced redox homeostasis is equally important in epithelial cells as well as myeloid cells during induction of colitis.
   - Support: Supported
   - Type: Secondary
   - Basis: parallel acute phenotypes support the interpretation, although the redox mechanism remains unresolved
   - Location: Abstract, Conclusions; Discussion, p. 21
4. Aggravation of acute DSS colitis in response to constitutive Nrf2 expression emphasizes the importance of tight regulation of Nrf2 during the onset of intestinal inflammation.
   - Support: Supported
   - Type: Secondary
   - Basis: acute aggravation is consistent, but the experiment does not directly identify the optimal regulatory range
   - Location: Abstract, Conclusions

## Strengths

- **Convergent acute findings across cell lineages** Constitutive Nrf2 activation increased acute DSS disease severity in both epithelial and myeloid models, with significant effects across complementary outcomes such as weight loss, colon length, and histology.
  - Dimension: contribution
  - Location: Results, Figures 1–2
- **Transparent multi-outcome experimental reporting** The study reports significant, null, and trend-level outcomes, including unchanged colonoscopy and MPO measurements rather than presenting only supportive endpoints. Endoscopic scoring was performed by a blinded independent investigator.
  - Dimension: methodological rigour
  - Location: Materials and Methods; Results, Figures 1–2
- **Direct engagement with contradictory evidence** The Discussion addresses Nrf2 knockout studies, sulforaphane and gallic-acid experiments, and divergent tissue-specific gain-of-function findings. It also distinguishes intermittent pharmacological activation from constitutive genetic activation.
  - Dimension: positioning
  - Location: Discussion, pp. 21–23

## Limitations

- **Multiplicity weakens secondary molecular findings** Numerous cytokine and gene-expression comparisons are reported across genotypes, treatments, lineages, and sexes without a stated multiplicity correction outside the RNA-sequencing analysis. This raises false-positive risk, particularly for Figure 7.
  - Dimension: methodological rigour
  - Location: Statistical Analysis; Results, Figures 3 and 7
- **Chronic comparison is statistically underpowered** The chronic model relies heavily on non-significant prolapse trends and sex-stratified analyses with n=4–8 for cytokine measurements. These data do not establish the acute-versus-chronic distinction with the same certainty as the acute findings.
  - Dimension: contribution
  - Location: Results, Figures 5–7
- **Therapeutic inference exceeds intervention tested** The proposed distinction between remission maintenance and acute-flare therapy extrapolates from constitutive genetic activation in mice to pharmacological treatment in patients. The article itself notes that transient drug activation may behave differently.
  - Dimension: application pathway
  - Location: Discussion, pp. 21–26

## Reliability checks

No concerns (4 of 4 checks).

- **Internal coherence:** Clean. The numerical findings, methods, and central conclusions are internally coherent, and null outcomes are reported alongside significant results. A single IL-20 reference in the chronic-colitis section is an evident typographical error for IL-10.
- **Research conduct:** Clean. Animal ethics authorization is declared and the RNA-sequencing data are assigned a GEO accession. No conflict-of-interest disclosure is visible in the supplied manuscript, but this is treated as an assessability gap rather than a conduct concern.
- **Reference integrity:** Clean. 70 of 70 checkable references verified
  - 70 references in manuscript
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
